1 / 3

PARADIGM-HF Objectives

PARADIGM-HF A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction. PARADIGM-HF Objectives.

hamal
Download Presentation

PARADIGM-HF Objectives

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PARADIGM-HFA multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction

  2. PARADIGM-HFObjectives

  3. PARADIGM-HFDesign Double-blind period Single-blind period LCZ696 200 mg BID (n~4000) LCZ 200 mg bid N = 7980 (1:1 randomization) LCZ 100 mg bid Enalapril 10 mg BID (n~4000) Enalapril 5-10 mg bid 1-2 weeks 1-2 weeks 2 weeks Outcomes driven (estimated mean f/u = 30-32 months) Prior ACEi/ARB use discontinued

More Related